62.3 Adult & Pediatric Attention-Deficit/Hyperactivity Disorder

ABFM Family Medicine Certification Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Blueprint & Clinical Decision-Making

1.1 Exam Blueprint, FMCLA vs. One-Day Exam & Board Scoring 1.2 Clinical Reasoning, Test-Taking Strategy & Ambiguity Management 1.3 Evidence-Based Medicine & Clinical Practice Guidelines in Primary Care

2 Chapter 2: Healthcare Systems, Practice Management & Quality

2.1 Practice Management, Billing, Coding & Documentation 2.2 Quality Improvement, Patient Safety & Diagnostic Stewardship 2.3 Interprofessional Team-Based Care & Care Coordination

3 Chapter 3: Ethics, Law, Biostatistics & Health Equity

3.1 Medical Ethics, Informed Consent & Surrogate Decision-Making 3.2 Biostatistics, Clinical Epidemiology & Diagnostic Test Interpretation 3.3 Social Determinants of Health, Health Equity & Cultural Humility 3.4 Physician Wellness, Burnout Prevention & Professionalism

4 Chapter 4: Lifestyle Counseling & Behavior Change

4.1 Alcohol Use Screening & Brief Intervention 4.2 Illicit Drug & Cannabis Counseling 4.3 Tobacco & Vaping Cessation Counseling

5 Chapter 5: Nutrition, Physical Activity & Chronic Disease Prevention

5.1 Dietary Counseling for Obesity & Chronic Disease Prevention 5.2 Exercise Prescription & Physical Activity Counseling 5.3 Genetic Risk Assessment & Family History Counseling

6 Chapter 6: Routine Adult Immunizations

6.1 ACIP Adult Respiratory Vaccines: Influenza, COVID-19, RSV & Pneumococcal 6.2 ACIP Adult Non-Respiratory Vaccines: Tdap, Shingrix, HPV & Hep B 6.3 Immunizations in Special Populations: Pregnancy, Asplenia & Immunocompromise

7 Chapter 7: Pediatric Health Maintenance & Surveillance

7.1 Newborn Examination & Early Postnatal Care 7.2 Well-Child Care, Developmental Surveillance & Milestones 7.3 Pediatric & Adolescent Screening: Vision, Hearing, Anemia & Lead 7.4 Pediatric Oral Health, Dental Screening & Fluoride

8 Chapter 8: Behavioral Health & Safety Screening

8.1 Primary Care Depression, Anxiety & Behavioral Health Screening 8.2 Domestic Violence, Intimate Partner Violence & Firearm Safety 8.3 Occupational Health & Recreational Safety Counseling

9 Chapter 9: Adult Preventive Screening: Cardiovascular & Metabolic

9.1 Cardiovascular Disease & Hypertension Screening 9.2 Type 2 Diabetes Screening & Prediabetes Risk Stratification 9.3 Abdominal Aortic Aneurysm & Osteoporosis Screening

10 Chapter 10: Adult Cancer Screening: Breast & Gynecologic

10.1 Breast Cancer Screening & Risk-Assessment 10.2 Cervical Cancer Screening & ASCCP Algorithms 10.3 Skin Cancer Clinical Assessment & Counseling

11 Chapter 11: Adult Cancer Screening: Colorectal, Lung & Prostate

11.1 Colorectal Cancer Screening Modalities & Intervals 11.2 Lung Cancer Screening with Low-Dose CT 11.3 Prostate Cancer Screening & Shared Decision-Making

12 Chapter 12: Sexual Health, Infectious Disease Screening & Contraception

12.1 Sexual Health Counseling & Risk-Reduction Strategies 12.2 STI Screening: Chlamydia, Gonorrhea, Syphilis & Trichomoniasis 12.3 Bloodborne Infectious Disease Screening: HIV & Hepatitis C

13 Chapter 13: Reproductive Life Planning, Lactation & Preoperative Care

13.1 Preconception Planning & Comprehensive Contraception Management 13.2 Lactation Support & Breastfeeding Counseling 13.3 Preoperative Medical Evaluation & Pre-Participation Sports Exam

14 Chapter 14: Emergent Cardiovascular Conditions

14.1 Acute Coronary Syndromes & Myocardial Infarction 14.2 Acute Chest Pain Risk Stratification & Triage 14.3 Acute or Critical Valvular Heart Emergencies

15 Chapter 15: Cardiac Arrhythmias, Heart Failure & Hypertensive Crises

15.1 Acute Atrial & Ventricular Arrhythmias 15.2 Acute Decompensated Heart Failure & Cardiogenic Shock 15.3 Hypertensive Emergency & Urgency Management

16 Chapter 16: Vascular & Thromboembolic Emergencies

16.1 Pulmonary Embolism & Deep Vein Thrombosis 16.2 Acute Aortic Syndromes & Peripheral Vascular Emergencies 16.3 Critical Limb Ischemia & Acute Arterial Occlusion

17 Chapter 17: Neurologic Emergencies: Stroke & Altered Consciousness

17.1 Acute Ischemic Stroke & Intracranial Hemorrhage 17.2 Syncope Evaluation & Status Epilepticus 17.3 Acute Delirium, Encephalopathy & Severe Confusion

18 Chapter 18: Neurologic Trauma & Acute Cranial Emergencies

18.1 Concussion, Moderate-to-Severe TBI & Intracranial Injury 18.2 Thunderclap & Acute Severe Secondary Headaches 18.3 Acute Ophthalmologic Emergencies

19 Chapter 19: Acute Abdominal, Pelvic & Gastrointestinal Emergencies

19.1 Acute Abdominal & Pelvic Pain Triage 19.2 Upper & Lower Gastrointestinal Bleeding 19.3 Acute Hepatic Failure, Cholangitis & Severe Jaundice

20 Chapter 20: Acute Pulmonary & Airway Emergencies

20.1 Acute Hypoxic Respiratory Failure & ARDS 20.2 Severe Community-Acquired Pneumonia & Empyema 20.3 Acute Severe Epistaxis & Airway Obstruction

21 Chapter 21: Acute Traumatic Injuries & Wound Care

21.1 Major Trauma Resuscitation & Initial Assessment 21.2 Burn Assessment, Inhalation Injury & Resuscitation 21.3 Laceration Management, Complex Wounds & Animal Bites

22 Chapter 22: Acute Orthopedic & Musculoskeletal Emergencies

22.1 Acute Ambulatory Fractures & Initial Splinting 22.2 Compartment Syndrome & Major Orthopedic Trauma 22.3 Septic Arthritis & Acute Microcrystalline Crises

23 Chapter 23: Severe Infections, Sepsis & Systemic Emergencies

23.1 Sepsis, Septic Shock & Initial Fluid Resuscitation 23.2 Necrotizing Soft Tissue Infections & Severe CNS Infections 23.3 Anaphylaxis Diagnosis, Epinephrine Dosing & Airway Protection

24 Chapter 24: Metabolic, Endocrine & Electrolyte Emergencies

24.1 Diabetic Ketoacidosis & Hyperosmolar Hyperglycemic State 24.2 Critical Electrolyte Emergencies: Dyskalemias & Dysnatremias 24.3 Severe Calcium Abnormalities & Acute Adrenal Crisis

25 Chapter 25: Hematologic, Urologic & Dental Emergencies

25.1 Severe Symptomatic Anemias & Coagulopathic Emergencies 25.2 Testicular Torsion, Priapism & Acute Urinary Retention 25.3 Urgent Odontogenic Infections & Dental Trauma

26 Chapter 26: Psychiatric, Behavioral & Obstetric/Gynecologic Emergencies

26.1 Suicidal Ideation, Acute Agitation & Behavioral Emergencies 26.2 Acute Physical & Sexual Assault Care 26.3 Life-Threatening Vaginal Bleeding & Ectopic Pregnancy 26.4 Environmental Heat Stroke & Severe Hypothermia

27 Chapter 27: Acute Head, Neck & Neurologic Symptoms

27.1 Primary Acute Headaches: Migraine, Tension & Cluster 27.2 Concussion & Minor Closed Head Injury Evaluation 27.3 Transient Ischemic Attack Evaluation & ABCD2 Risk Scoring

28 Chapter 28: Acute Cranial Nerves, Hearing & Sensory Symptoms

28.1 Peripheral Neuropathies: Bell's Palsy, Carpal Tunnel & Radiculopathy 28.2 Acute Tinnitus, Sudden Sensorineural Hearing Loss & Cerumen Impaction 28.3 Acute Dizziness, Benign Paroxysmal Positional Vertigo & Vestibular Neuritis

29 Chapter 29: Acute Upper Respiratory Tract Infections

29.1 Acute Viral Rhinosinusitis vs. Bacterial Rhinosinusitis 29.2 Acute Pharyngitis: Group A Streptococcus & Centor Criteria 29.3 Acute Otitis Media, Otitis Externa & Serous Effusion

30 Chapter 30: Acute Lower Respiratory Infections & Cough

30.1 Influenza, COVID-19 & Viral Respiratory Syndromes 30.2 Acute Bronchitis & Lower Respiratory Tract Infections 30.3 Ambulatory Community-Acquired Pneumonia

31 Chapter 31: Allergic, Nasal & Non-Infectious Pulmonary Conditions

31.1 Allergic Rhinitis & Acute Non-Anaphylactic Allergic Reactions 31.2 Acute Dyspnea in Ambulatory Care 31.3 Interstitial Lung Diseases & Sarcoidosis Presentation

32 Chapter 32: Acute Chest, Cardiac & Vascular Symptoms

32.1 Palpitations Evaluation & Arrhythmia Triage in Primary Care 32.2 Deep Vein Thrombosis & Superficial Thrombophlebitis 32.3 Ambulatory Hypotension & Orthostasis Evaluation

33 Chapter 33: Acute Upper Gastrointestinal Conditions

33.1 Peptic Ulcer Disease & Gastritis 33.2 Dysphagia, Esophagitis & Acute Esophageal Disorders 33.3 Acute Nausea, Vomiting & Foodborne Illness

34 Chapter 34: Acute Lower Gastrointestinal Conditions

34.1 Acute Infectious Diarrhea & Gastroenteritis 34.2 Acute Constipation & Functional Bowel Changes 34.3 Ano-Rectal Disorders: Hemorrhoids, Fissures, Abscesses & Pruritus Ani

35 Chapter 35: Inflammatory, Functional & Malabsorptive GI Disorders

35.1 Acute Flares of Inflammatory Bowel Disease 35.2 Irritable Bowel Syndrome: Diagnosis, Subtyping & Management 35.3 Celiac Disease & Malabsorption Syndromes

36 Chapter 36: Acute Abdominal, Hepatic & Biliary Disorders

36.1 Ambulatory Abdominal & Pelvic Pain Triage 36.2 Acute Cholecystitis, Biliary Colic & Pancreatitis 36.3 Acute Liver Injury & Viral Hepatitis

37 Chapter 37: Acute Abdominal Wall, Hernias & Dental Conditions

37.1 Abdominal Wall, Inguinal & Ventral Hernias 37.2 Acute Dental Pain, Odontogenic Abscess & Aphthous Ulcers 37.3 Acute Edema: Unilateral vs. Bilateral Diagnostic Evaluation

38 Chapter 38: Acute Infectious Dermatoses

38.1 Bacterial Skin Infections: Impetigo, Cellulitis & Cutaneous Abscesses 38.2 Fungal Skin Infections: Tinea Corporis, Cruris, Pedis & Onychomycosis 38.3 Viral Cutaneous Infections: Herpes Simplex, Zoster & Molluscum Contagiosum

39 Chapter 39: Inflammatory, Allergic & Autoimmune Dermatoses

39.1 Atopic Dermatitis, Contact Dermatitis & Eczematous Flares 39.2 Non-Infectious Rashes: Urticaria, Drug Eruptions & Erythema Multiforme 39.3 Cutaneous Malignancies & Premalignant Lesions: AK, BCC, SCC & Melanoma

40 Chapter 40: Acute Shoulder, Elbow & Upper Extremity Injuries

40.1 Rotator Cuff Pathology, Tendinopathy & Shoulder Impingement 40.2 Lateral & Medial Epicondylitis, Olecranon Bursitis & Elbow Sprains 40.3 Wrist & Hand Soft-Tissue Injuries: De Quervain, TFCC & Finger Sprains

41 Chapter 41: Acute Knee, Ankle & Lower Extremity Injuries

41.1 Meniscal Tears, Ligamentous Knee Injuries & Patellofemoral Pain 41.2 Ankle Sprains, Ottawa Ankle Rules & Achilles Tendinopathy 41.3 Plantar Fasciitis, Shin Splints & Overuse Syndromes

42 Chapter 42: Acute Ambulatory Fractures & Dislocations

42.1 Distal Radius, Scaphoid & Common Upper Extremity Fractures 42.2 Metatarsal, Clavicle & Common Lower Extremity Fractures 42.3 Joint Dislocation Management: Nursemaid's Elbow & Shoulder Subluxation

43 Chapter 43: Acute Axial Musculoskeletal Pain & Falls

43.1 Acute Low Back Pain: Red Flags, Strain & Disc Herniation 43.2 Acute Cervical Strain, Whiplash & Axial Neck Pain 43.3 Evaluation of Falls in Ambulatory & Older Patients

44 Chapter 44: Acute Inflammatory Arthropathies & Generalized Pain

44.1 Acute Inflammatory Arthritis & Spondyloarthropathies 44.2 Myalgias, Rhabdomyolysis & Post-Viral Pain Syndromes 44.3 Acute Non-Headache Pain Management Strategies

45 Chapter 45: Acute Renal, Urinary & Genitourinary Conditions

45.1 Uncomplicated UTI, Pyelonephritis & Acute Urethritis 45.2 Hematuria Workup & Glomerulonephritis 45.3 Nephrolithiasis & Acute Urinary Tract Obstruction

46 Chapter 46: Acute Male Genitourinary & Prostatic Conditions

46.1 Acute Prostatitis, Epididymitis & Orchitis 46.2 Acute Scrotal Pain: Torsion vs Appendage, BPH & Male Genital Emergencies 46.3 Acute Urinary Retention & Incontinence Evaluation

47 Chapter 47: Acute Women's Health & Early Pregnancy Care

47.1 Early Pregnancy Diagnosis, Dating & Initial Complications 47.2 Abnormal Uterine Bleeding & Acute Menstrual Disorders 47.3 Premenstrual Syndrome & Premenstrual Dysphoric Disorder

48 Chapter 48: Breast Disorders, STIs & Pediatric Elimination

48.1 Palpable Breast Mass, Mastitis & Nipple Discharge 48.2 Sexually Transmitted Infections: Diagnosis, Staging & CDC Guidelines 48.3 Pediatric Enuresis & Encopresis

49 Chapter 49: Systemic Signs, Metabolic Dysregulation & Miscellaneous Infections

49.1 Acute Fever, Sepsis Screening & FUO in Primary Care 49.2 Acute Hyperglycemia & Symptomatic Hypoglycemia 49.3 Electrolyte Abnormalities: Mild-to-Moderate Disturbances 49.4 Vector-Borne, Tick-Borne & Rickettsial Illnesses

50 Chapter 50: Chronic Cardiovascular Diseases: Hypertension & Ischemia

50.1 Essential Hypertension Management: 2025 AHA/ACC Guideline & JNC Strategies 50.2 Chronic Coronary Artery Disease & Post-MI Secondary Prevention 50.3 Chronic Heart Failure: HFrEF, HFpEF & Quadruple GDMT

51 Chapter 51: Chronic Vascular, Valvular & Dyslipidemic Diseases

51.1 Peripheral Arterial Disease & Claudication 51.2 Chronic Valvular Heart Disease & Murmur Evaluation 51.3 Lipid Disorders & ASCVD Risk-Based Statin Therapy

52 Chapter 52: Chronic Respiratory Diseases: Asthma & COPD

52.1 Chronic Asthma Management: GINA Stepwise SMART Therapy 52.2 Chronic Obstructive Pulmonary Disease: GOLD Recommendations 52.3 Solitary Pulmonary Nodule Evaluation & Fleischner Society Criteria

53 Chapter 53: Chronic Metabolic Diseases: Diabetes Mellitus

53.1 Type 2 Diabetes Management: ADA Pharmacotherapy Algorithms 53.2 Type 1 Diabetes: Basal-Bolus Insulin, CGMs & Diabetic Complications 53.3 Diabetic Microvascular & Macrovascular Disease Surveillance

54 Chapter 54: Obesity, Nutrition & Metabolic Bone Diseases

54.1 Medical & Behavioral Management of Obesity & Incretin Mimetics 54.2 Osteoporosis & Metabolic Bone Disease: DEXA, FRAX & Antiresorptives 54.3 Nutritional Deficiencies: Vitamin D, B12, Iron & Malnutrition

55 Chapter 55: Chronic Endocrine Disorders

55.1 Primary & Subclinical Hypothyroidism, Hyperthyroidism & Nodules 55.2 Adrenal Disorders: Addison's Disease & Cushing's Syndrome 55.3 Hypercalcemia, Hyperparathyroidism & Pituitary Disorders

56 Chapter 56: Chronic Kidney Disease & Venous Disorders

56.1 Chronic Kidney Disease: KDIGO Staging & Renoprotective Therapy 56.2 Chronic Venous Insufficiency, Stasis Dermatitis & Lymphedema 56.3 Chronic Electrolyte & Acid-Base Management in CKD

57 Chapter 57: Chronic Gastrointestinal & Hepatic Diseases

57.1 Gastroesophageal Reflux Disease, Barrett's Esophagus & Dyspepsia 57.2 Chronic Liver Disease: MASLD/NAFLD, Cirrhosis & Portal Hypertension 57.3 Viral Hepatitis B & C: Long-Term Monitoring & DAA Therapy

58 Chapter 58: Colorectal Surveillance & Chronic Pancreaticobiliary Care

58.1 Post-Polypectomy Colorectal Polyp Surveillance Guidelines 58.2 Chronic Pancreatitis & Exocrine Pancreatic Insufficiency 58.3 Chronic Nausea, Gastroparesis & Functional GI Disorders

59 Chapter 59: Chronic Musculoskeletal & Rheumatologic Disorders

59.1 Osteoarthritis: Hip, Knee & Hand Management 59.2 Spinal Conditions: Spinal Stenosis, Spondylolisthesis & Compression Fractures 59.3 Chronic Myopathies & Fibromyalgia Syndrome

60 Chapter 60: Chronic Neurologic & Neurodegenerative Disorders

60.1 Dementia: Alzheimer's, Vascular & Lewy Body Disease 60.2 Parkinson's Disease & Essential Tremor 60.3 Epilepsy: Chronic Antiseizure Medications & Post-Stroke Care

61 Chapter 61: Chronic Peripheral Nerves, Pain & Sensory Disorders

61.1 Diabetic & Chronic Peripheral Neuropathies 61.2 Chronic Pain Syndromes & Chronic Daily Headaches 61.3 Chronic Tinnitus, Presbycusis & Persistent Dizziness

62 Chapter 62: Chronic Psychiatric Disorders

62.1 Major Depressive Disorder & Generalized Anxiety Disorder 62.2 Bipolar Disorder: Maintenance Pharmacotherapy & Lithium Monitoring 62.3 Adult & Pediatric Attention-Deficit/Hyperactivity Disorder

63 Chapter 63: Chronic Behavioral Health & Neurodevelopmental Conditions

63.1 Chronic Behavioral Conditions: PTSD, OCD & Somatization 63.2 Autism Spectrum Disorder & Intellectual Disabilities 63.3 Eating Disorders: Anorexia Nervosa, Bulimia & Binge Eating

64 Chapter 64: Chronic Substance Use Disorders & Tobacco Cessation

64.1 Alcohol Use Disorder: Pharmacotherapy & Relapse Prevention 64.2 Opioid & Stimulant Use Disorders: MOUD & Harm Reduction 64.3 Longitudinal Tobacco Cessation Pharmacotherapy

65 Chapter 65: Chronic Dermatologic Conditions

65.1 Acne Vulgaris, Rosacea & Seborrheic Dermatitis 65.2 Chronic Plaque Psoriasis & Biologic Therapies 65.3 Chronic Eczema, Hidradenitis Suppurativa & Cutaneous Lupus

66 Chapter 66: Chronic Reproductive, Infectious & Geriatric Special Care

66.1 Chronic Menstrual Disorders, Infertility & Sexual Dysfunction 66.2 Menopause Management & Hormone Replacement Therapy 66.3 Chronic HIV Infection Management & Primary Care Integration 66.4 Gender-Affirming Primary Care & Hormone Therapy 66.5 Advance Care Planning, Palliative Care & End-of-Life Symptom Control

67 Chapter 67: Continuity Care: Sleep, Fatigue, Cancer, Pregnancy & the Adult Preventive Visit

67.1 Chronic Insomnia & Obstructive Sleep Apnea 67.2 Chronic Malaise, Fatigue & ME/CFS 67.3 Primary Care During Cancer Treatment & Survivorship 67.4 Routine Prenatal Care & Longitudinal Pregnancy Management 67.5 The Periodic Adult Health Examination & Medicare Annual Wellness Visit

62.3 Adult & Pediatric Attention-Deficit/Hyperactivity Disorder

Key Takeaways Explain This Topic AI

ADHD diagnosis under DSM-5 requires persistent inattention and/or hyperactivity-impulsivity causing marked functional impairment across at least two independent settings (e.g., home and school/work), with several symptoms documented prior to age 12; diagnostic thresholds mandate at least 6 symptoms for children (<17 years) and at least 5 symptoms for adolescents and adults (>=17 years).

Per American Academy of Pediatrics (AAP) guidelines, preschool-aged children (4-5 years) must receive evidence-based Parent Training in Behavior Management (PTBM) as first-line therapy; school-aged children (6-11 years) and adolescents require FDA-approved pharmacotherapy combined with behavioral interventions and school accommodations (504 Plan/IEP).

First-line stimulants (methylphenidate- and amphetamine-based formulations) demonstrate a 70-80% clinical response rate by blocking dopamine and norepinephrine reuptake and promoting catecholamine release; routine baseline electrocardiogram (ECG) is NOT required in asymptomatic children with normal personal and family cardiac histories.

Non-stimulant medications include atomoxetine (selective NRI; non-controlled, 4-6 week onset, black box warning for suicidality) and alpha-2 adrenergic agonists (guanfacine ER and clonidine ER; ideal for comorbid tics, ODD, or insomnia, but requiring mandatory slow taper to prevent rebound hypertensive crisis).

Responsible controlled substance stewardship requires checking state Prescription Drug Monitoring Programs (PDMP), executing written treatment agreements, conducting baseline and periodic random urine drug testing, and meticulously charting pediatric height and weight velocity on standardized growth curves.

Last updated: September 2026

Explicit Curriculum Focus: Attention-Deficit/Hyperactivity Disorder (Appendix A CC_167)

Attention-Deficit/Hyperactivity Disorder (ADHD) is a chronic, highly heritable neurodevelopmental disorder characterized by developmentally inappropriate levels of inattention, hyperactivity, and impulsivity. Affecting approximately 8% to 10% of school-aged children and adolescents, ADHD was historically misconceptualized as a self-limiting childhood behavioral problem. Longitudinal epidemiological studies demonstrate that ADHD persists into adulthood in 50% to 60% of individuals , affecting approximately 4% to 5% of the adult workforce. In adulthood, untreated ADHD is associated with severe occupational instability, relationship breakdown, financial delinquency, substance use disorders, motor vehicle collisions, and elevated all-cause mortality. FRONTO-SUBCORTICAL DYSREGULATION IN ADHD

• Genetic Polymorphisms (DAT1, DRD4, NET) & Environmental Neurodevelopmental Risks
• │
• ▼
• Hypoactive Catecholaminergic Tone in Prefrontal-Striatal Networks
• │
• ┌──────────────────────────────┴──────────────────────────────┐
• ▼ ▼
• Prefrontal Norepinephrine (NE) Deficiency Prefrontal Dopamine (DA) Deficiency
• Decreased stimulation of postsynaptic • Decreased stimulation of postsynaptic
• alpha-2A adrenergic receptors dopamine D1 receptors
• Weakened signal transmission in working memory • Increased background noise and distractibility
• Inability to sustain attention & focus • Impaired behavioral inhibition & impulsivity
• │
• ▼
• Executive Dysfunction, Emotional Dysregulation, & Working Memory Deficits
• Neurobiology: The Catecholamine Signal-to-Noise Paradigm

Functional neuroimaging and molecular pharmacology demonstrate that ADHD is driven by structural and functional hypoactivity within the prefrontal cortex (PFC), anterior cingulate cortex, and striatum (caudate and putamen) . The PFC governs executive functions: sustaining attention, organizing tasks, suppressing extraneous environmental distractions, delaying gratification, and regulating emotional responses.

Alpha-2A Receptors Enhance the "Signal" : Postsynaptic α 2 A \alpha_{2A} α 2 A ​ -adrenergic receptors in prefrontal dendritic spines strengthen relevant neuronal network connections, enhancing the signal of the task at hand and sustaining working memory.

Dopamine D1 Receptors Dampen the "Noise" : Postsynaptic dopamine D1 receptors decrease inappropriate, irrelevant synaptic inputs, effectively suppressing extraneous background noise.

Pathological Catecholamine Depletion : In patients with ADHD, excessive clearance of synaptic dopamine by the dopamine transporter (DAT) and norepinephrine by the norepinephrine transporter (NET) leaves the prefrontal cortex catecholamine-deficient. This degrades the signal-to-noise ratio, rendering the brain unable to prioritize tasks, resist impulses, or sustain mental effort.

DSM-5-TR Diagnostic Criteria for ADHD

Under DSM-5-TR, establishing a diagnosis of ADHD requires a comprehensive evaluation demonstrating a persistent pattern of inattention and/or hyperactivity-impulsivity that interferes with functioning or development, as characterized by Domain 1 (Inattention) and/or Domain 2 (Hyperactivity and Impulsivity) . DSM-5 SYMPTOM THRESHOLDS FOR ADHD

• Age Category Threshold for Diagnosis (Per Domain)
• ═════════════════════════════════════════════════════════════════════════════════════════════════════════════
• Children (< 17 years) At least 6 of 9 symptoms present for at least 6 consecutive months
• Adolescents & Adults (>= 17 years) At least 5 of 9 symptoms present for at least 6 consecutive months

═════════════════════════════════════════════════════════════════════════════════════════════════════════════ THE NINE INATTENTION SYMPTOMS (DOMAIN 1)

1. Careless Mistakes: Fails to give close attention to details or makes careless mistakes in schoolwork,

work duties, or other activities.

2. Sustaining Attention: Often has difficulty sustaining attention in tasks or play activities (lectures,

lengthy reading, conversations).

3. Appears Not to Listen: Often does not seem to listen when spoken to directly (mind seems elsewhere).

4. Incomplete Follow-Through: Often fails to follow through on instructions and fails to finish schoolwork,

chores, or workplace obligations.

5. Disorganization: Often has difficulty organizing tasks and activities (poor time management, messy work,

misses deadlines).

6. Avoids Sustained Mental Effort: Avoids, dislikes, or is reluctant to engage in tasks requiring sustained

cognitive effort (reports, forms).

7. Loses Essential Items: Frequently loses materials necessary for tasks (school assignments, eyeglasses,

keys, wallet, phone).

8. Easily Distracted: Easily distracted by extraneous stimuli (or unrelated intrusive thoughts in adults).

• 9. Forgetful in Daily Activities: Forgetful in daily routines (chores, running errands, returning calls,
• paying bills, appointments). THE NINE HYPERACTIVITY & IMPULSIVITY SYMPTOMS (DOMAIN 2)

1. Fidgets / Squirms: Often fidgets with or taps hands or feet, or squirms uncomfortably in seat.

2. Leaves Seat: Leaves seat in situations when remaining seated is expected (classroom, office, dinner table).

3. Inappropriate Running/Climbing: Runs about or climbs in situations where it is inappropriate (in adults,

limited to subjective restlessness).

4. Unable to Play Quietly: Often unable to play or engage in leisure activities quietly.

5. "Driven by a Motor": Often "on the go," acting as if driven by an internal motor; uncomfortable being still.

6. Excessive Talking: Often talks excessively in social or professional settings.

7. Blurts Out Answers: Often blurts out an answer before a question has been fully completed; finishes sentences.

8. Difficulty Waiting Turn: Often has profound difficulty waiting their turn (in line, in traffic, in conversation).

9. Interrupts / Intrudes: Often interrupts or intrudes on others (butts into conversations, games, or meetings).

The Five Essential Diagnostic Stipulations

To confirm a valid ADHD diagnosis, the patient must fulfill all five DSM-5 stipulations:

Symptom Threshold : Meets symptom criteria in Inattention, Hyperactivity/Impulsivity, or both for at least 6 months.

Age of Onset Prior to 12 Years : Several inattentive or hyperactive-impulsive symptoms must have been present prior to age 12 years . In adult evaluations, this requires retrospective collateral confirmation via childhood school report cards or interviews with parents/older siblings.

Pervasiveness Across Multiple Settings : Several symptoms must be manifest in TWO OR MORE SETTINGS (e.g., at home AND at school/work; with friends/relatives; in extracurricular activities). A child who exhibits disruptive behavior strictly at home or strictly in one classroom does not have ADHD.

Functional Impairment : Clear evidence that symptoms significantly interfere with or reduce the quality of social, academic, or occupational functioning.

Alternative Etiology Exclusion : Symptoms do not occur exclusively during the course of schizophrenia or another psychotic disorder and are not better accounted for by another mental disorder (e.g., mood disorder, generalized anxiety disorder, PTSD, sleep apnea, or substance intoxication/withdrawal).

Clinical Presentations & The Adult Phenotype

ADHD manifests in three distinct presentations based on symptom distribution over the preceding 6 months:

Combined Presentation : Fulfills both Inattention AND Hyperactivity-Impulsivity criteria. Most common overall presentation in clinical practice.

Predominantly Inattentive Presentation : Fulfills Inattention criteria, but falls short of Hyperactivity-Impulsivity thresholds. Historically underdiagnosed, especially in females . Girls with inattentive ADHD present as quiet, daydreaming, disorganized, and easily fatigued, frequently mislabeled as anxious or unmotivated until academic demands overwhelm executive functioning in high school or college.

Predominantly Hyperactive/Impulsive Presentation : Fulfills Hyperactivity-Impulsivity criteria without significant inattentive deficits. Most common in preschool and early elementary school boys; least common in adults.

The Metamorphosis of Adult ADHD

As individuals mature, overt motor hyperactivity (running, climbing, jumping) typically attenuates due to fronto-striatal maturation. However, the core neurobiological deficit shifts into distinct adult phenotypes: PEDIATRIC VS. ADULT ADHD MANIFESTATIONS

• Pediatric Manifestation Adult Manifestation & Real-World Complication
• ═════════════════════════════════════════════════════════════════════════════════════════════════════════════
• Running around, leaving seat Internal subjective restlessness; inability to relax; fidgeting with

pens/phones; overbooking schedule; intolerance of quiet environments.

• ─────────────────────────────────────────────────────────────────────────────────────────────────────────
• Blurting out answers in class Interrupting colleagues; conversational impatience; impulsive career

resignations; explosive road rage; impulsive online shopping.

• ─────────────────────────────────────────────────────────────────────────────────────────────────────────
• Disorganized backpack / lost toys Chronic procrastination; severe time blindness; chronic lateness;

unpaid bills; tax delinquency; messy home/desk; missed project deadlines.

• ─────────────────────────────────────────────────────────────────────────────────────────────────────────
• Temper tantrums / fighting Emotional dysregulation; rejection sensitive dysphoria (RSD); low

frustration tolerance; rapid emotional lability; marital discord.

• ═════════════════════════════════════════════════════════════════════════════════════════════════════════════
• Standardized Rating Scales & Diagnostic Workup

An accurate ADHD diagnosis requires systematic multi-informant documentation utilizing validated rating instruments:

Pediatric Scales (Ages 6 to 12 Years) :

Vanderbilt ADHD Diagnostic Rating Scales : The gold standard in primary care. Includes validated Parent and Teacher forms . Assesses all 18 DSM symptoms alongside validated comorbidity screening subscales for Oppositional Defiant Disorder (ODD), Conduct Disorder (CD), and anxiety/depression. Both parent and teacher forms must demonstrate cross-setting impairment.

Conners 3 Rating Scales : Comprehensive multi-informant scales covering ages 6 to 18 years.

Adult Rating Scales :

Adult ADHD Self-Report Scale (ASRS v1.1) : Developed with the World Health Organization; features a highly validated 6-item screening tool and a full 18-item symptom checklist.

Objective Diagnostic Testing Trap : Computerized Continuous Performance Tests (CPTs, e.g., TOVA, QbTest) and neuroimaging are NOT recommended or required for clinical diagnosis by the AAP or AACAP, as they suffer from poor sensitivity and specificity.

AAP Stepwise Management Algorithm by Age Group

The American Academy of Pediatrics (AAP) 2019 Clinical Practice Guideline delineates a rigorous, age-stratified management pathway: AAP STEPWISE ADHD TREATMENT BY AGE GROUP

• Age Group First-Line Intervention Second-Line / Adjunctive Options
• ═════════════════════════════════════════════════════════════════════════════════════════════════════════════
• Preschool-Aged EVIDENCE-BASED PARENT TRAINING Methylphenidate pharmacotherapy
• Children (Ages 4-5) IN BEHAVIOR MANAGEMENT (PTBM) ONLY IF behavioral therapy fails and

and classroom behavioral interventions. moderate-to-severe dysfunction persists.

• ─────────────────────────────────────────────────────────────────────────────────────────────────────────
• School-Aged Children FDA-APPROVED MEDICATIONS Behavioral classroom interventions;
• (Ages 6-11) COMBINED WITH PTBM and educational IEP under IDEA or 504 Plan accommodations;

accommodations (IEP / 504 Plan). non-stimulant alternatives.

• ─────────────────────────────────────────────────────────────────────────────────────────────────────────
• Adolescents FDA-APPROVED MEDICATIONS with Behavioral therapies, executive skills
• (Ages 12-18) adolescent assent, COMBINED WITH coaching, 504 Plan with extended time;

educational accommodations. substance risk mitigation.

• ═════════════════════════════════════════════════════════════════════════════════════════════════════════════
• Educational Accommodations: 504 Plans vs. IEPs

Primary care physicians frequently write medical necessity letters for academic accommodations:

Section 504 Plan (Rehabilitation Act) : Provides civil-rights accommodations for physical or mental impairments that substantially limit major life activities. Common accommodations include: extended time on examinations (1.5x to 2x) , preferential seating at the front of the classroom away from doors/windows, quiet testing environments, chunking long assignments into smaller milestones, and permission to take scheduled movement breaks.

Individualized Education Program (IEP; IDEA Act) : Required when the student requires specialized, modified educational instruction and specialized learning goals beyond simple classroom accommodations.

First-Line Pharmacotherapy: Stimulant Medications

Stimulants represent the most effective pharmacotherapeutic class in psychiatric medicine, demonstrating clinical response rates of 70% to 80% (compared to 40% to 50% for non-stimulants). If a patient fails to respond to one stimulant class, there is a 50% likelihood of robust response to the alternative class; systematic trialing of both classes yields an overall response rate exceeding 85% to 90%. STIMULANT PHARMACOLOGY & FORMULATIONS

• Stimulant Class Mechanism of Action Formulations & Brand Names Clinical Pearls
• ═════════════════════════════════════════════════════════════════════════════════════════════════════════════
• Methylphenidate- Selectively blocks DAT & NET • Short-Acting: Ritalin, Preferred first-line in
• Based Formulations transporters, preventing Focalin (dexmethylphenidate) children and adolescents;
• catecholamine reuptake. • Long-Acting: Concerta better side-effect profile;
• Does not promote release. (OROS), Focalin XR, Aptensio, transdermal patch (Daytrana)

Daytrana patch, Cotempla. available for swallowing issues.

• ─────────────────────────────────────────────────────────────────────────────────────────────────────────
• Amphetamine- Blocks DAT & NET reuptake • Short-Acting: Adderall, Often preferred in adults;
• Based Formulations AND promotes reverse-transport Dexedrine, Zenzedi more potent catecholamine
• vesicular catecholamine • Long-Acting: Adderall XR, release; Lisdexamfetamine
• release into synaptic cleft. Vyvanse (lisdexamfetamine), has lowest diversion risk

Mydayis, Dynavel, Adzenys. due to prodrug cleavage.

• ═════════════════════════════════════════════════════════════════════════════════════════════════════════════
• The Lisdexamfetamine Prodrug Mechanism

Lisdexamfetamine (Vyvanse) is an inactive prodrug in which d-amphetamine is covalently bonded to the essential amino acid L-lysine. Following oral ingestion, it is absorbed intact from the gastrointestinal tract into the portal circulation. Enzymatic hydrolysis by aminopeptidases on the surface of red blood cells cleaves the peptide bond, gradually liberating free active d-amphetamine.

Pharmacokinetic Benefit : Provides smooth, predictable 12- to 14-hour therapeutic coverage without sharp plasma peaks and valleys.

Tamper Resistance & Diversion Mitigation : Because therapeutic activation requires systemic enzymatic cleavage by red blood cells, snorting (intranasal) or intravenous injection yields no rapid euphoric high , dramatically reducing illicit abuse and diversion potential on college campuses.

Formulations: Prioritizing Long-Acting Agents

Extended-release (long-acting) formulations are strongly preferred over immediate-release agents for routine chronic management:

Eliminates the need for midday administration by the school nurse, removing social stigma and medication theft.

Provides smooth, all-day coverage encompassing homework, after-school activities, and evening family interactions.

Prevents sharp rebound behavioral crashes and emotional irritability when short-acting levels plummet.

Significantly blunts the reinforcing euphoria associated with rapid plasma peaks, minimizing addiction and street diversion.

Stimulant Adverse Effects & Actionable Clinical Management STIMULANT ADVERSE EFFECTS & CLINICAL MITIGATION

• Adverse Reaction Incidence & Pathophysiology Actionable Clinical Management Strategy
• ═════════════════════════════════════════════════════════════════════════════════════════════════════════════
• Appetite Suppression Affects 50-60% of patients; central • Administer medication DURING or AFTER a large,

and Weight Loss hypothalamic appetite suppression. nutrient-dense breakfast.

• Provide calorie-dense evening dinners and

bedtime snacks when stimulant wears off.

• Liquid nutritional supplements (shakes).

• ─────────────────────────────────────────────────────────────────────────────────────────────────────────
• Growth Velocity Transient reduction in height velocity • Monitor height and weight on CDC growth charts

Attenuation (~1-2 cm over 1-3 years); adult height at EVERY visit.

is minimally affected. • Consider planned "drug holidays" on weekends

or summer breaks if severe growth failure.

─────────────────────────────────────────────────────────────────────────────────────────────────────────

Sleep-Onset Insomnia Delayed sleep latency from evening • Ensure extended-release taken early in morning.

stimulant receptor occupancy. • Strict sleep hygiene (remove screens/devices).

• Add evening low-dose Guanfacine or Clonidine.

• ─────────────────────────────────────────────────────────────────────────────────────────────────────────
• Afternoon Rebound Rebound irritability, tantrums, or • Transition to longer-acting formulation;
• Dysphoria / Irritability hyperactivity as drug clears. • Add a tiny "booster" dose of short-acting

stimulant (e.g., 2.5-5 mg) in late afternoon.

• ─────────────────────────────────────────────────────────────────────────────────────────────────────────
• Mild Vital Sign Changes Mean increase in HR (3-6 bpm) and • Monitor vitals at every visit;

BP (2-4 mmHg systolic/diastolic). • Discontinue or add alpha-2 agonist if severe.

• ═════════════════════════════════════════════════════════════════════════════════════════════════════════════
• Cardiovascular Safety & The Baseline ECG Question

A perennial board-examination question addresses pre-treatment cardiovascular screening in ADHD:

The Consensus Guideline (AAP / AHA / ACC) : A routine baseline 12-lead electrocardiogram (ECG) is NOT REQUIRED in asymptomatic children with an unremarkable personal and family cardiac history and a completely normal physical examination.

Mandatory Pre-Treatment Cardiac History Screen (Red Flags) :

History of exertional syncope, presyncope, exertional chest pain, or excessive exertional dyspnea.

History of pathologic cardiac murmurs, arrhythmias, or hypertension.

Family history of sudden, unexplained cardiac death in family members younger than 40 years .

Family history of hypertrophic cardiomyopathy (HCM), Long QT syndrome, Brugada syndrome, arrhythmogenic right ventricular cardiomyopathy (ARVC), or Wolff-Parkinson-White (WPW) syndrome.

Actionable Rule : If any cardiac red flag is identified in personal or family history, stimulant initiation must be deferred pending pediatric cardiology clearance, 12-lead ECG, and echocardiography .

Non-Stimulant Medications: Atomoxetine & Alpha-2 Agonists

Non-stimulant medications are indicated when stimulants produce intolerable side effects (severe anorexia, unmanageable insomnia, severe motor tics), when active substance use disorders create unacceptable diversion risks, or as adjunctive therapy for refractory symptoms. NON-STIMULANT PHARMACOTHERAPY FOR ADHD

• Medication Mechanism & Dosing Clinical Pearls & Niches Adverse Effects & Black Box Warnings
• ═════════════════════════════════════════════════════════════════════════════════════════════════════════════
• Atomoxetine Selective Norepinephrine • Non-controlled substance; • DELAYED ONSET: Requires 4 to 6

(Strattera) Reuptake Inhibitor (NRI). zero abuse liability. WEEKS for full therapeutic efficacy.

Start 0.5 mg/kg/day, titrate to • Excellent for comorbid • BLACK BOX WARNING: Increased suicidal

target 1.2-1.4 mg/kg/day (max anxiety or substance abuse. ideation in children/young adults.

100 mg daily). Once/twice daily. • Smooth 24-hr coverage. • Nausea, fatigue; rare hepatotoxicity.

• ─────────────────────────────────────────────────────────────────────────────────────────────────────────
• Guanfacine ER Selective postsynaptic • Excellent for comorbid • Sedation, somnolence, dizziness,

(Intuniv) alpha-2A adrenergic receptor tics/Tourette syndrome, bradycardia, orthostatic hypotension.

• agonist in prefrontal cortex. ODD, impulsivity, insomnia.• CRITICAL WARNING: NEVER STOP
• Dose: 1 to 4 mg once daily Can be monotherapy or ABRUPTLY! Taper slowly to prevent

in the evening. adjunctive to stimulants. life-threatening REBOUND HYPERTENSION.

• ─────────────────────────────────────────────────────────────────────────────────────────────────────────
• Clonidine ER Non-selective alpha-2 adrenergic • Potent sedative; excellent • Significantly more sedating and

(Kapvay) agonist (alpha-2A, 2B, 2C). for severe hyperactivity, hypotensive than guanfacine.

Dose: 0.1 to 0.4 mg once daily severe aggression, insomnia.• Rebound hypertension risk on abrupt

at bedtime (or divided BID). • High efficacy in tics. discontinuation.

─────────────────────────────────────────────────────────────────────────────────────────────────────────

Viloxazine ER Selective Norepinephrine • Approved in pediatric & • BLACK BOX WARNING: Suicidal ideation.

(Qelbree) Reuptake Inhibitor (NRI). adult ADHD; non-controlled.• Strong CYP1A2 inhibitor (contra-

Dose: 100-400 mg once daily. • Fast-acting non-stimulant. indicated with theophylline, tizanidine).

• ═════════════════════════════════════════════════════════════════════════════════════════════════════════════
• Atomoxetine: The Delayed-Onset Non-Stimulant

Atomoxetine selectively blocks the norepinephrine transporter (NET). Because NET clears both norepinephrine and dopamine in the prefrontal cortex, atomoxetine boosts both neurotransmitters in the PFC without increasing dopamine in the nucleus accumbens, resulting in zero euphoria and zero abuse liability (non-scheduled agent).

The Critical Clinical Difference from Stimulants : While stimulants work immediately on the first day of administration, atomoxetine requires 4 to 6 weeks of continuous daily administration to achieve therapeutic efficacy . Clinicians must prepare families for this delayed onset to prevent premature drug abandonment.

Safety Monitoring : The FDA issued a black box warning for increased suicidal thoughts in children and adolescents . Rare, severe idiosyncratic hepatotoxicity can occur; instruct patients to discontinue the drug and contact the clinic immediately for jaundice, dark urine, or unexplained right upper quadrant tenderness.

Alpha-2 Agonists: Guanfacine ER and Clonidine ER

Centrally acting alpha-2 agonists directly stimulate postsynaptic α 2 A \alpha_{2A} α 2 A ​ receptors in the prefrontal cortex, mimicking endogenous norepinephrine and strengthening prefrontal network connectivity. They are uniquely effective for patients with ADHD and comorbid tic disorders (Tourette syndrome) , oppositional defiant disorder (ODD), physical aggression, or stimulant-induced insomnia.

Selectivity : Guanfacine is 15- to 20-fold more selective for α 2 A \alpha_{2A} α 2 A ​ receptors than clonidine, producing far less sedation and hypotension.

The Board-Style Critical Red Flag: Rebound Hypertensive Crisis :

Centrally acting alpha-2 agonists suppress sympathetic outflow from the vasomotor center in the brainstem.

Abrupt cessation triggers a massive, life-threatening sympathoadrenal rebound surge with profound hypertension, tachycardia, severe headache, tremors, diaphoresis, and risk of hypertensive encephalopathy or stroke.

Mandatory Tapering Protocol : When discontinuing guanfacine or clonidine, the dose MUST BE TAPERED SLOWLY (e.g., reducing guanfacine by no more than 1 mg every 3 to 7 days; clonidine by 0.1 mg every 3 to 7 days).

Controlled Substance Stewardship & Regulatory Management

Because stimulants are DEA Schedule II controlled substances, family physicians must balance compassionate, effective clinical care with rigorous medico-legal stewardship to prevent misuse and diversion:

Prescription Drug Monitoring Program (PDMP) : Mandatorily check the state PDMP database prior to the initial prescription and periodically at every follow-up visit to verify adherence, identify multi-provider prescribing, and detect co-prescribed sedatives or opioids.

Controlled Substance Treatment Agreement : Execute a signed formal treatment agreement detailing prescription boundaries: medications taken strictly as prescribed, no early refills under any circumstances for 'lost' or 'stolen' pills, single-prescriber and single-pharmacy rules, and mandatory agreement to submit to random urine drug screening.

Urine Drug Testing (UDT/UDS) : Perform baseline and random periodic urine drug screens. Verify two distinct findings : (1) the presence of the prescribed stimulant (confirming patient adherence), and (2) the absence of illicit substances (cocaine, unprescribed amphetamines, non-prescribed opioids, benzodiazepines).

Routine Monitoring Schedule : Stable patients maintained on stimulants require clinical reassessment at least every 3 to 6 months to monitor resting blood pressure, pulse, weight, growth velocity, rating scales, and medication compliance.

Loading diagram... ADHD Diagnostic Assessment, Age-Stratified Treatment, and Pharmacotherapy Selection Algorithm